Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. The company is headquartered in Hayward, California and currently employs 61 full-time employees. The company went IPO on 2016-05-18. The firm uses Nano-Pulse Stimulation technology, an energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. The company has developed CellFX System, which is a tunable, software-enabled, console-based platform, designed to accommodate the clinical workflow preferred by physicians. The CellFX System is configured to accept a variety of handpieces or electrodes across a range of clinical applications. The company has developed a cardiac ablation clamp for use in cardiac surgery and a cardiac ablation catheter for use in electrophysiology. The Company’s cardiac ablation clamp and cardiac ablation catheter both use the CellFX System to generate its proprietary pulses of electrical energy. Its surgical cardiac ablation clamp is designed for use by cardiac surgeons during the surgical treatment.